Daniel Cressy, a 23-year-old from New Orleans, is the first person in Louisiana to be functionally cured of sickle cell disease [1], [2].
This milestone demonstrates the real-world application of CRISPR gene-editing technology to treat hereditary blood disorders that previously required lifelong management. For patients like Cressy, the therapy represents a shift from treating symptoms to correcting the underlying genetic cause.
Cressy received Casgevy, an FDA-approved CRISPR-based gene-editing therapy [4]. The treatment process involved editing his own stem cells to correct the sickle-cell mutation, which then allowed his body to produce healthy hemoglobin [4], [5].
Before the treatment, the disease caused severe health complications for the New Orleans resident. Cressy had previously been hospitalized up to 12 times per year [3]. The functional cure eliminates the need for these frequent emergency interventions.
The announcement of his recovery occurred on June 24, 2026 [1], [5]. While some reports describe him as the first in the region to be functionally cured, other sources specify he is the first in the state [1], [2].
"It’s my greatest blessing," Cressy said [1].
Casgevy works by targeting the genetic instructions in a patient's bone marrow. By editing these cells, the therapy prevents the red blood cells from taking on the crescent shape characteristic of the disease, a process that typically leads to excruciating pain and organ damage.
“"It’s my greatest blessing."”
The successful application of Casgevy in Louisiana highlights the expanding accessibility of CRISPR technology within the U.S. healthcare system. While functional cures offer a transformative quality of life for individual patients, the broader challenge remains the high cost and complex infrastructure required to administer gene-editing therapies to the wider sickle cell population.
